San Francisco, California, July 03, 2018: The global market for neurological biomarkers is the focus of analysis of a recent market research report by TMR Research. The report, titled “Neurological Biomarkers Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025,” is a detailed assessment of the growth dynamics of the market in the past and present years along with an evaluation of potential future growth prospects of the market over the period between 2017 and 2025.
Get Sample Copy of this Report @
The significant rise in prevalence of neurological diseases across the globe has compelled several pharmaceutical companies to invest their efforts in research and development activities aimed at the development of effective drug candidates to treat these brain-altering conditions. Funds being poured towards this cause will be the key to the overall development of the global neurological biomarkers market in the near future. The demand for effective neurological biomarkers drugs will also be driven due to the rising geriatric population globally, which is a demographic most vulnerable to neurological diseases.
Initiatives undertaken by governments of several developed as well as developing countries to increase awareness about the need for proper management of neurological diseases and funds to support research and development efforts will also drive the market. Moreover, an increasing number of drug candidates appearing in clinical trials hint at a promising future in the field of neurological biomarkers.
Read Comprehensive Overview of Report @
The high expenditure required to undertake research and development activities in the field of neurological diseases has kept many potential small- and medium-scale companies out of the larger neurological biomarker research and development market. This has slowed down the rate of development of new and innovative drug candidates in the market, limiting the growth prospects of the market to a certain extent. Nevertheless, the vast set of untapped growth opportunities across emerging economies is expected to provide market leaders with promising growth prospects.
Some of the leading companies operating in the global neurological biomarkers market are Acumen Pharmaceuticals, Cisbio Bioassays, AbaStar MDx, QIAGEN N.V., Myriad RBM, Thermo Fisher Scientific, Athena Diagnostics, Proteome Sciences, Abiant, and Aepodia.